South Korea-based Genome & Company (KOSDAQ 314130) has made a significant investment in List Labs and List Biotherapeutics, with plans to attract further investment and grow the company’s strong legacy position in microbiome therapeutics – specifically with construction of the new phase III and commercial CDMO facility.

As a pioneer in clinical manufacturing for LBP-based therapeutics, List Labs has a strong pipeline of clients that need state-of-the-art phase III and commercial manufacturing. With this growth-oriented investment strategy and an additional therapeutics pipeline from Genome & Company, List Labs is seeking to build on 45 years of expertise to become the microbiome therapeutic sector’s leading CDMO.